Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Placebo-controlled, Double-blind, Parallel Group Study to Investigate the Safety, Tolerability and Pharmacokinetics of Increasing Single Oral Doses of BAY2328065 Including the Relative Bioavailability Between Solution and Tablet Formulation and the Effect of Food on the Pharmacokinetics of BAY2328065 in Healthy Men

Trial Profile

Randomized, Placebo-controlled, Double-blind, Parallel Group Study to Investigate the Safety, Tolerability and Pharmacokinetics of Increasing Single Oral Doses of BAY2328065 Including the Relative Bioavailability Between Solution and Tablet Formulation and the Effect of Food on the Pharmacokinetics of BAY2328065 in Healthy Men

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Jan 2019

At a glance

  • Drugs BAY-2328065 (Primary) ; BAY-2328065 (Primary)
  • Indications Endometriosis
  • Focus Adverse reactions
  • Sponsors Bayer
  • Most Recent Events

    • 21 Jan 2019 Planned End Date changed from 4 Feb 2019 to 11 Feb 2019.
    • 20 Dec 2018 Planned End Date changed from 15 Jan 2019 to 4 Feb 2019.
    • 24 Oct 2018 Planned End Date changed from 9 Jan 2019 to 15 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top